After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis, a biotech firm, has successfully raised $800 million and is aiming for a public offering to target previously deemed 'undruggable' disease targets. This comes on the heels of a significant trend in biotech IPOs, indicating a robust funding environment for innovative healthcare companies.
Parabilis IPO biotech healthcare funding
Linked Entities
Contributing Articles
United States releases a $2 billion investment in quantum computing with IBM's participation, strengthening strategic technological infrastructure and accelerating the development of advanced processors that can change the internet, digital security, and
CPG Click Petróleo e Gás —
5/23/26 National Security and Korean News and Commentary
Small Wars Journal —
Uncle Sam's $2B Quantum Gift: Buy D-Wave, Skip Rigetti
Seeking Alpha —
Space Force awards Viasat, SES $437 million for military satellite network
SpaceNews —
The Pentagon’s $54 billion bet on autonomous warfare
Defense One —
The Week’s 10 Biggest Funding Rounds: Massive Deals For Medical Devices, Futuristic AI Gadgets And Frontier Labs Lead
Crunchbase News —
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials
Seeking Alpha —
A Colorado startup just raised $30 million to send a second rover to the Moon — and the real bet isn't on exploration, it's on becoming the construction crew that arrives before the astronauts do
Space Daily —
D Wave Quantum Wins US$100 Million CHIPS Act Backing As Losses Widen
Yahoo Finance —
U.S. Plans to Invest $2 Billion and Take Stake in Quantum Firms
The New York Times —